- Press Releases
- Notices
Press Releases To List
-
- Jun.24.2025R & D
- Ono and Bristol-Myers Squibb KK Receive Supplemental Approval of Opdivo® and Yervoy® in Combination Treatment in Japan to Expand the Use for Unresectable Hepatocellular Carcinoma
-
- Jun.23.2025Licensing
- Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
-
- Jun.19.2025Management / Finance
- Notice of Disposal of Treasury Shares as Tenure-based Restricted Stock Compensation and Performance-linked Restricted Stock Compensation
-
- May.29.2025R & D
- Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
-
- May.28.2025R & D
- ONO PHARMA Presents Positive Results from Pivotal Trial in U.S. Patients with Relapsed or Refractory PCNSL at 2025 ASCO Annual Meeting
Notices To List
-
- Jun.20.2025Corporate
- Voting Results (Extraordinary Report) of the 77th Ordinary General Shareholders’ Meeting
-
- Jun.19.2025Corporate
- Notice to Resolutions Passed at The 77th Ordinary General shareholders’ Meeting
-
- Jun.11.2025Corporate
- Notice about Posting of R&D Day - ASCO PROSPECT Study Data Presentation - Script
-
- May.28.2025Corporate
- Notice about Posting of R&D Day - ROMVIMZA - Script
-
- May.22.2025Corporate
- Notice to Convene the 77th Ordinary General Shareholders' Meeting
About
We Want to Deliver New Drugs
to the World with a Wish.
For more than 300 years since its foundation in 1717, working for people’s health.
Diseases still unconquered. Patients' wishes still unfulfilled.
ONO, with a wish to meet these medical needs, devotes all its efforts to drug discovery.
